The first pneumococcal conjugate vaccine (PCV) was licensed more than 25 years ago in the USA and Europe, but its marketing authorisation was based on efficacy studies using a 3+1 dosing regimen, ...

FDA drug alerts in pulmonology, including drug approvals/warnings, vaccine approvals, medical device recalls/updates, and ...

In the Philippines, historically poor regulation of antibiotic dispensing has been identified as one of the factors ...

Against influenza and COVID-19 certainly, and for the elderly and the more susceptible, against respiratory syncytial virus (RSV) and pneumococcal pneumonia, too. Vaccines, while not absolutely ...

In fact, in the second quarter, we grew 11% year-over-year ex exchange ... We're now in 31 markets, competing really well in the marketplace for patients with pneumococcal disease. And likewise, we ...

More than 23,000 Cuban children have so far been vaccinated against pneumococcus using the drug Pneumosil 10-valent, which ...

Vaxcyte’s shot covers an additional 11 strains than Prevnar 20 ... the stock market reaction indicates Wall Street sees it as a potential competitor to pneumococcal vaccines from Pfizer, Merck & Co.

The overall spread of respiratory viruses has been fairly low this season, according to the Centers for Disease Control and ...

The South African National Department of Health today proudly celebrated the 10th Anniversary of MomConnect, a flagship ...

Antimicrobial resistance and serotypes in Streptococcus pneumoniae have been evolving with the widespread use of antibiotics and the introduction of pneumococcal conjugate vaccines (PCV).

However, increase in disease-causing or colonizing pneumococcal strains with intermediate resistance due to selective pressure can become a clinical concern. Therefore, changing trends should be ...

Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD. Just-reported ...